Figure 2. Overall survival of patients under atezolizumab (IO/C-IO) and chemotherapy (C) when available, who experienced grade 1–2, 3–4 (time-varying) irAEs in four cancer indications: non-small cell lung cancer and small cell lung cancer (a); renal cell carcinoma (b); urothelial bladder cancer (c); and triple-negative breast cancer (d). TRT=treatment regimen as follows: C=chemotherapy regimen or chemotherapy with bevacizumab; C-IO=treatment with atezolizumab in combination with chemotherapy or bevacizumab; IO=treatment with atezolizumab monotherapy. irAEs, immune-related adverse events were reported in all study arms, including standard of care without atezolizumab, given the blinded nature of the controlled trials; NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer; TNBC, triple-negative breast cancer.